Sandbox c30
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease. | It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330.<scene name='Sandbox_c30/Inhibidor/1'>(W84 and F330)</scene> |
Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9031-5. PMID:8415649 | Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9031-5. PMID:8415649 | ||
Revision as of 13:07, 23 November 2010
|
Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor.
It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease.
Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330.
Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9031-5. PMID:8415649
